Organisation paid for research Program year 2025 Source: CMS Open Payments

Methodist Health System

Neither a doctor nor a teaching hospital

Research payments

$283,592

184 payments

Through program year 2025, Methodist Health System is reported as receiving $283,592 in research payments, across 184 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $102,146 60
2024 Research $130,534 95
2023 Research $29,270 8
2022 Research $600 1
2020 Research $6,400 7
2019 Research $14,642 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. Intercept Pharmaceuticals, Inc. $82,241 43 payments
  2. Bausch Health US, LLC $81,180 77 payments
  3. Ipsen Pharma SAS $73,929 39 payments
  4. GlaxoSmithKline, LLC. $41,792 21 payments
  5. Bard Peripheral Vascular, Inc. $2,775 3 payments
  6. Davol Inc. $1,675 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $81,180 77 payments
  2. A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity $73,929 39 payments
  3. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis $70,460 34 payments
  4. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $24,600 4 payments
  5. A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Ev $17,192 17 payments
  6. A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis $11,781 9 payments
  7. Ultrascore Registry Bpv16001 $2,775 3 payments
  8. Phasix Dvl-He-011 $1,675 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record